BriaCell Therapeuticsの空売りは7月に18.4%減少し、機関投資家が出資を増やし、HC Wainwrightは「買い」の格付けを維持しました。 BriaCell Therapeutics' short interest declined 18.4% in July, with Institutional investors increasing stakes, and HC Wainwright maintaining a "buy" rating.

乳がんの進行段階の第3相試験中のBriaCell Therapeuticsは,7月にショート利息が18.4%減少し,569,400から464,400株に減少しました. BriaCell Therapeutics, in Phase 3 trials for advanced breast cancer, saw a 18.4% decline in short interest in July, dropping from 569,400 to 464,400 shares. National Bank of Canada FI、Onyx Bridge Wealth Group LLC、K.J. Institutional investors like National Bank of Canada FI, Onyx Bridge Wealth Group LLC, and K.J. ハリソン&パートナーズ社は 4Q中に株を増やしました Harrison & Partners Inc increased their stakes during Q4. HCウェインライトは"買える"と評価され,目標価格が18ドルです. HC Wainwright maintains a "buy" rating and an $18.00 price target. BCTXは第2四半期に0.11ドルのEPSを報告し,分析者の推定値を0.66ドル上回った. BCTX reported $0.11 EPS in Q2, exceeding analyst estimates by $0.66.